Personalis (PSNL) AI Stock Analysis

• Market Cap: $791.44M
• Dividend Yield: N/A
• Average Volume (3M): 1.17M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.92
• Revenue Growth: 0.36%
• EPS Growth: 22.13%
• Country: US
• Employees: 228
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.23
• Shares Outstanding: 88,677,060
• 10 Day Avg. Volume: 1,572,400
• 30 Day Avg. Volume: 1,168,774
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.57
• Enterprise Value/Revenue: 5.61
• Enterprise Value/Gross Profit: 17.84
• Enterprise Value/Ebitda: -5.58
• 1Y Price Target: $7.58
• Price Target Upside: -19.79% Downside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 54 Neutral
• Price Target: $9.00 ▼(-4.76% Downside)

Personalis' stock score is primarily influenced by its financial performance challenges, including declining revenues and profitability issues. While technical analysis shows positive momentum, valuation remains a concern due to negative earnings. The company's strategic focus on clinical adoption and potential reimbursement catalysts offers some optimism for future growth.

Positive Factors

Clinical Adoption Growth

The rapid growth in clinical adoption of NeXT Personal indicates strong market acceptance and potential for sustained revenue growth in precision oncology.

MRD Market Potential

The large addressable market for MRD provides a substantial growth opportunity for Personalis, enhancing long-term revenue prospects as they capture market share.

Strategic Partnerships

Strategic collaborations, like with Tempus, expand Personalis' reach and validate its technology, supporting sustainable growth through diversified applications.

Negative Factors

Revenue Decline

The significant revenue decline highlights challenges in maintaining sales momentum, which could impact long-term financial stability if not addressed.

Profitability Challenges

Increasing net losses indicate ongoing profitability challenges, which may strain financial resources and hinder investment in growth initiatives.

Gross Margin Pressure

Declining gross margins suggest cost management issues, potentially impacting the company's ability to achieve sustainable profitability in the long term.

Personalis Business Overview & Revenue Model

Company Description

Personalis, Inc. (PSNL) is a biotechnology company that specializes in providing advanced genomic sequencing and analysis services. The company operates primarily within the healthcare sector, focusing on personalized medicine and genomic data analysis. Personalis's core products include its comprehensive genomic profiling solutions that enable precision oncology, allowing for tailored treatment plans based on an individual’s unique genetic makeup. By leveraging cutting-edge technology and proprietary algorithms, Personalis aims to improve patient outcomes and facilitate the development of targeted therapies.

How the Company Makes Money

Personalis generates revenue primarily through its genomic sequencing services, which are utilized by pharmaceutical companies, academic institutions, and healthcare providers. The company offers a range of products and services, including whole exome and custom gene panel sequencing, as well as bioinformatics analysis. Key revenue streams include contracts with pharmaceutical companies for companion diagnostics and clinical trials, where Personalis provides genomic insights to support drug development. Additionally, the company has established partnerships with leading cancer centers and research institutions, contributing to its earnings through collaborative research projects and service agreements. Personalis also benefits from reimbursement for its services through health insurance providers, further enhancing its revenue model.

Personalis Financial Statement Overview

Summary

Personalis displays mixed financial health with strong equity positions, yet struggles with profitability and cash flow negativity. Revenue growth provides some optimism, but operational losses and cash flow issues are concerning. The company must strategically manage costs and leverage growth opportunities to improve financial performance.

Income Statement

The company shows a mixed performance on the income statement. The TTM (Trailing-Twelve-Months) Gross Profit Margin stands at 33.31%, which indicates a reasonable level of profitability, albeit with high operational costs reflected in negative EBIT and EBITDA margins. The Net Profit Margin is significantly negative at -98.10%, highlighting ongoing losses. Revenue growth is positive at 3.20% year-over-year, suggesting some potential for future revenue expansion despite current challenges.

Balance Sheet

Personalis maintains a solid balance sheet, with a Debt-to-Equity ratio of 0.21, indicating low leverage and financial stability. The Equity Ratio is strong at 75.88%, showing substantial equity funding. However, despite a positive Return on Equity of -40.54%, the company operates at a loss, impacting overall financial health.

Cash Flow

Cash flow analysis reveals challenges with negative free cash flow, though the Free Cash Flow to Net Income Ratio of 0.56 suggests some alignment between cash outflows and net loss. The Operating Cash Flow to Net Income Ratio at 0.51 indicates cash operations are not fully supporting net income, a risk factor for liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	80.32M	84.61M	73.48M	65.05M	85.49M	78.65M
Gross Profit	25.26M	26.82M	18.21M	13.35M	31.66M	20.11M
EBITDA	-80.80M	-70.30M	-96.81M	-104.64M	-59.01M	-34.05M
Net Income	-91.32M	-81.28M	-108.30M	-113.31M	-65.23M	-41.28M
Balance Sheet
Total Assets	258.68M	270.27M	225.10M	292.70M	396.53M	244.84M
Cash, Cash Equivalents and Short-Term Investments	173.23M	185.01M	114.18M	167.66M	287.06M	203.29M
Total Debt	42.44M	44.25M	48.96M	48.65M	52.80M	10.99M
Total Liabilities	67.85M	67.31M	95.66M	74.56M	86.23M	49.90M
Stockholders Equity	190.83M	202.96M	129.44M	218.14M	310.30M	194.94M
Cash Flow
Free Cash Flow	-49.18M	-46.75M	-67.17M	-120.13M	-81.91M	-45.90M
Operating Cash Flow	-44.89M	-45.15M	-56.26M	-70.23M	-70.83M	-42.65M
Investing Cash Flow	-81.28M	-35.07M	13.10M	52.54M	-60.07M	-65.14M
Financing Cash Flow	131.79M	114.67M	11.03M	1.37M	169.70M	121.27M

Personalis Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.45
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PSNL, the sentiment is Positive. The current price of 9.45 is above the 20-day moving average (MA) of 8.13, above the 50-day MA of 6.42, and above the 200-day MA of 5.31, indicating a bullish trend. The MACD of 0.92 indicates Negative momentum. The RSI at 62.51 is Neutral, neither overbought nor oversold. The STOCH value of 48.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PSNL.

Personalis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDNA	63 Neutral	$775.78M	14.40	20.73%	―	14.72%	―
FLGT	61 Neutral	$719.31M	―	-4.54%	―	4.31%	69.57%
CSTL	59 Neutral	$688.66M	―	-2.15%	―	20.40%	-165.41%
MYGN	55 Neutral	$731.33M	―	-70.03%	―	3.83%	-137.31%
PSNL	54 Neutral	$791.44M	―	-60.26%	―	0.36%	22.13%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LAB	44 Neutral	$527.15M	-4.43	-22.40%	―	13.17%	64.50%

Personalis Corporate Events

Personalis Secures New VA Contract Task Order

On August 19, 2025, Personalis, Inc. announced a new task order under its contract with the U.S. Department of Veterans Affairs for the Million Veteran Program, effective September 30, 2025, valued at up to $13.5 million. This order increases the cumulative value of task orders received by Personalis under its contracts with the VA MVP to approximately $225.0 million, highlighting the company’s significant role in this large-scale genomic research initiative.

The most recent analyst rating on (PSNL) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Personalis stock, see the PSNL Stock Forecast page.

Personalis Earnings Call: Growth Amidst Financial Challenges

During the recent earnings call, Personalis presented a mixed sentiment with a blend of optimism and challenges. While the company showcased strong growth in clinical adoption and a promising partnership with Tempus, it faced hurdles with revenue declines and biopharma challenges. However, a robust cash position and potential Medicare coverage were highlighted as positive indicators for future prospects.

Personalis Reports Q2 2025 Financial Results

Personalis, Inc., based in Fremont, California, is a leader in advanced genomics for precision oncology, specializing in personalized cancer testing to guide patient care and enhance drug development strategies.